Stock Analysis

Waldencast Full Year 2024 Earnings: EPS Misses Expectations

NasdaqCM:WALD
Source: Shutterstock

Waldencast (NASDAQ:WALD) Full Year 2024 Results

Key Financial Results

  • Revenue: US$273.9m (up 26% from FY 2023).
  • Net loss: US$42.4m (loss narrowed by 53% from FY 2023).
  • US$0.38 loss per share (improved from US$0.89 loss in FY 2023).
revenue-and-expenses-breakdown
NasdaqCM:WALD Revenue and Expenses Breakdown March 22nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Waldencast EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 95%.

The primary driver behind last 12 months revenue was the Obagi segment contributing a total revenue of US$149.3m (55% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$201.8m (82% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$11.1m. Explore how WALD's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Personal Products industry in the US.

Performance of the American Personal Products industry.

The company's shares are down 3.1% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Waldencast that you need to be mindful of.

Valuation is complex, but we're here to simplify it.

Discover if Waldencast might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.